Glenmark receives tentative ANDA approval for Topiramate extended-release capsules

24 Jan 2019 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Topiramate Extended?Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, a generic version of QUDEXY XR Extended?Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, of Upsher- Smith Laboratories, LLC.

According to IQVIA sales data for the 12 month period ending November 2018, the QUDEXY XR Extended?Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg market achieved annual sales of approximately $84.0 million.

The company’s current portfolio consists of 148 products authorized for distribution in the US marketplace and 54 ANDA’s pending approval with the USFDA. In addition to these internal filings, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. 

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

1031.00 -11.70 (-1.12%)
19-Apr-2024 13:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1511.20
Dr. Reddys Lab 5903.50
Cipla 1346.30
Zydus Lifesciences 917.45
Lupin 1544.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.